| Literature DB >> 26442916 |
Joseph J Knapik1,2,3, Ryan A Steelman4, Sally S Hoedebecke5, Krista G Austin6,7, Emily K Farina6,7, Harris R Lieberman6.
Abstract
BACKGROUND: Dietary supplements (DSs) are commercially available products consumed as an addition to the usual diet and are frequently ingested by athletes.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26442916 PMCID: PMC4697915 DOI: 10.1007/s40279-015-0387-7
Source DB: PubMed Journal: Sports Med ISSN: 0112-1642 Impact factor: 11.136
Fig. 1Publications included and excluded at each stage of literature review
Methodological quality scores at various publication times
| Publication date (year grouping) | Studies ( | Methodological quality score (mean ± SD) | One way analysis of variance |
|---|---|---|---|
| 1969–1989 | 38 | 37 ± 15 | 0.04 |
| 1990–1999 | 32 | 45 ± 14 | |
| 2000–2009 | 50 | 43 ± 13 | |
| 2010–2014 | 39 | 46 ± 16 |
SD standard deviation
Summary data on prevalence of dietary supplement use of athletes by sport and sex
| Sport | Subgroup | Dietary supplement | Studies | Nationality | Individual study prevalence (%) | Total sample size ( | SPE [% (S95 % CI)] | Homogeneity of SPE | |
|---|---|---|---|---|---|---|---|---|---|
|
|
| ||||||||
| Football | College men | Any vitamin | Jonnalagadda 2001 [ | US | 23 | ||||
| Cole et al. 2005 [ | US | 4 | 59 | 11 (2–48) | 0.06 | 71 | |||
| Creatine | Greenwood et al. 2000 [ | US | 67 | ||||||
| Jonnalagadda et al. 2001 [ | US | 36 | 107 | 52 (23–80) | <0.01 | 88 | |||
| High school males | Creatine | Swirzinski 2000 [ | US | 29 | |||||
| Scofield and Unruh 2006 [ | US | 26 | 182 | 29 (23–36) | 0.77 | 0 | |||
| Any vitamin or mineral | Sobal 1994 [ | US | 39 | ||||||
| Scofield and Unruh 2006 [ | US | 17 | 95 | 31 (14–56) | 0.16 | 50 | |||
| Soccer | Elite men | Any DS | Tscholl et al. 2008 [ | Mixed | 43 | ||||
| Aljaloud and Ibrahim 2013 [ | Saudi Arabian | 93 | 1577 | 76 (15–98) | <0.01 | 98 | |||
| Any vitamin | Burke et al. 1991 [ | Australian | 14 | ||||||
| Waddington et al. 2005 [ | UK | 58 | 2234 | 39 (26–55) | <0.01 | 95 | |||
| Tscholl et al. 2008 [ | Mixed | 42 | |||||||
| Amino acids | Tscholl et al. 2008 [ | Mixed | 8 | ||||||
| Aljaloud and Ibrahim 2013 [ | Saudi Arabian | 25 | 841 | 14 (4–38) | <0.01 | 96 | |||
| Creatine | Waddington et al. 2005 [ | UK | 37 | ||||||
| Tscholl et al. 2008 [ | Mixed | 8 | 2283 | 17 (5–47) | <0.01 | 99 | |||
| Aljaloud and Ibrahim 2013 [ | Saudi Arabian | 15 | |||||||
| Body-building | Men | Any DS | Faber 1987 [ | South African | 63 | ||||
| Linseisen et al. 1993 [ | German | 100 | 337 | 82 (57–94) | <0.01 | 90 | |||
| Karimian et al. 2011 [ | Iranian | 87 | |||||||
| Any vitamin | Brill and Keane 1994 [ | US | 70 | ||||||
| Karimian et al. 2011 [ | Iranian | 52 | 460 | 61 (43–77) | <0.01 | 93 | |||
| Any mineral | Brill and Keane 1994 [ | US | 49 | ||||||
| Karimian et al. 2011 [ | Iranian | 15 | 460 | 29 (7–68) | <0.01 | 98 | |||
| MVM | Faber 1987 [ | South African | 37 | ||||||
| Sandoval et al. 1989 [ | US | 20 | 128 | 42 (29–55) | 0.18 | 42 | |||
| Andersen et al. 1995 [ | US | 51 | |||||||
| Vit A | Faber 1987 [ | South African | 10 | ||||||
| Karimian et al. 2011 [ | Iranian | 11 | 324 | 11 (8–15) | 0.68 | 0 | |||
| Vit B or B complex | Faber 1987 [ | South African | 14 | ||||||
| Andersen et al. 1995 [ | Iranian | 28 | 123 | 20 (9–39) | 0.04 | 76 | |||
| Vit C | Faber 1987 [ | South African | 31 | ||||||
| Andersen et al. 1995 [ | Iranian | 46 | 123 | 38 (24–55) | 0.08 | 68 | |||
| Protein | Faber 1987 [ | South African | 59 | ||||||
| Linseisen et al. 1993 [ | German | 100 | 346 | 63 (44–79) | <0.01 | 83 | |||
| Brill and Keane 1994 [ | US | 61 | |||||||
| Andersen et al. 1995 [ | US | 38 | |||||||
| Amino acids | Brill and Keane 1994 [ | US | 51 | ||||||
| Andersen et al. 1995 [ | US | 58 | 259 | 52 (46–58) | 0.44 | 0 | |||
| Women | Any DS | Walberg-Rankin et al. 1993 [ | US | 100 | |||||
| Karimian et al. 2011 [ | Iranian | 11 | 256 | 50 (1–99) | <0.01 | 89 | |||
| Any vitamin | Brill and Keane 1994 [ | US | 76 | ||||||
| Karimian et al. 2011 [ | Iranian | 4 | 349 | 27 (1–96) | <0.01 | 99 | |||
| Any mineral | Brill and Keane 1994 [ | US | 57 | ||||||
| Karimian et al. 2011 [ | Iranian | 10 | 349 | 28 (3–81) | <0.01 | 99 | |||
| MVM | Sandoval et al. 1989 [ | US | 50 | ||||||
| Walberg-Rankin et al. 1993 [ | US | 33 | 12 | 42 (18–70) | 0.56 | 0 | |||
| Iron | Walberg-Rankin et al. 1993 [ | US | 17 | ||||||
| Karimian et al. 2011 [ | Iranian | 5 | 256 | 6 (3–15) | 0.25 | 23 | |||
| Calcium | Walberg-Rankin et al. 1993 [ | US | 17 | ||||||
| Karimian et al. 2011 [ | Iranian | 7 | 256 | 8 (5–12) | 0.4 | 0 | |||
| Protein | Walberg-Rankin et al. 1993 [ | US | 50 | ||||||
| Brill and Keane 1994 [ | US | 54 | 105 | 53 (44–63) | 0.87 | 0 | |||
| Amino acids | Walberg-Rankin et al. 1993 [ | US | 100 | ||||||
| Brill and Keane 1994 [ | Iranian | 59 | 105 | 73 (27–95) | 0.13 | 55 | |||
| Ballet | Elite women | Any DS | Calabrese et al. 1983 [ | US | 40 | ||||
| Zenic et al. 2010 [ | Croatian | 76 | 46 | 59 (23–87) | 0.02 | 83 | |||
| Triathlon | Men | Any DS | Burke et al. 1991 [ | Australian | 44 | ||||
| Knez and Peake 2010 [ | Mixed | 58 | 256 | 54 (48–60) | 0.53 | 0 | |||
| Dolan et al. 2011 [ | US | 55 | |||||||
| Women | Any DS | Knez and Peake 2010 [ | Mixed | 69 | |||||
| Dolan et al. 2011 [ | US | 53 | 207 | 56 (44–67) | 0.27 | 19 | |||
| Dance | Women | Any DS | Evers 1987 [ | US | 48 | ||||
| Sekulic et al. 2008 [ | Serbian | 24 | 67 | 30 (19–49) | 0.11 | 55 | |||
| Zenic et al. 2010 [ | Croatian | 18 | |||||||
| Sport drink | Sekulic et al. 2008 [ | Serbian | 24 | ||||||
| Zenic et al. 2010 [ | Croatian | 18 | 46 | 22 (12–36) | 0.1 | 76 | |||
| Ultra- marathon | Men | Magnesium | Peters and Goetzsche 1997 [ | Mixed | 70 | ||||
| Knechtle et al. 2008 [ | Mixed | 45 | 170 | 60 (35–81) | 0.03 | 79 | |||
CI confidence interval, DS dietary supplement, MVM multivitamins/multiminerals, SPE summary prevalence estimate, S95 % CI summary 95 % CI, vit vitamin
Use of selected dietary supplement by elite and non-elite athletic status
| Dietary supplement | Status | Sex | Studies | Nationality | Individual study prevalence (%) | Total sample size ( | SPE [% (S95 % CI)] | Homogeneity of SPE | Trim and fill evaluation | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
| Imputed studies ( | Adjusted SPE [% (S95 % CI)] | ||||||||
| Any DS | Elite | Men | Houston 1980 [ | Canadian | 75 | 2297 | 69 (60–78) | <0.01 | 94 | 6 | 55 (45–65) |
| Snyder et al. 1989 [ | US | 60 | |||||||||
| Kleiner et al. 1990 [ | US | 90 | |||||||||
| Berglund 2001 [ | Swedish | 28 | |||||||||
| Sundgot-Borgen et al. 2003 [ | Norwegian | 51 | |||||||||
| Ziegler et al. 2003 [ | US | 65 | |||||||||
| Nieper 2005 [ | UK | 55 | |||||||||
| Huang et al. 2006 [ | Canadian | 71 | |||||||||
| Dascombe et al. 2010 [ | Australian | 89 | |||||||||
| Kondric et al. 2010 [ | Slovenian | 94 | |||||||||
| Kim et al. 2010 [ | Korean | 79 | |||||||||
| Kim et al. 2011 [ | Korean | 79 | |||||||||
| Lazic et al. 2011 [ | Serbian | 61 | |||||||||
| Women | Houston 1980 [ | Canadian | 50 | 1634 | 71 (62–79) | <0.01 | 90 | 6 | 60 (50–69) | ||
| Snyder et al. 1989 [ | US | 86 | |||||||||
| Kleiner et al. 1990 [ | US | 100 | |||||||||
| Berglund 2001 [ | Swedish | 40 | |||||||||
| Sundgot-Borgen et al. 2003 [ | Norwegian | 54 | |||||||||
| Ziegler et al. 2003 [ | US | 76 | |||||||||
| Nieper et al. 2005 [ | UK | 75 | |||||||||
| Huang et al. 2006 [ | Canadian | 73 | |||||||||
| Dascombe et al. 2010 [ | Australian | 86 | |||||||||
| Kondric et al. 2010 [ | Slovenian | 83 | |||||||||
| Kim et al. 2010 [ | Korean | 82 | |||||||||
| Kim et al. 2011 [ | Korean | 82 | |||||||||
| Lazic et al. 2011 [ | Serbian | 61 | |||||||||
| Non elite | Men | Nowak et al. 1988 [ | US | 6 | 952 | 48 (27–70) | <0.01 | 97 | 0 | 48 (27–70) | |
| Neiman et al. 1989 [ | US | 30 | |||||||||
| Peters and Goetzsche 1997 [ | South African | 75 | |||||||||
| Sekulic et al. 2008 [ | Serbian | 14 | |||||||||
| Knez and Peake 2010 [ | Mixed | 58 | |||||||||
| Karimian et al. 2011 [ | Iranian | 87 | |||||||||
| Dolan et al. 2011 [ | US | 55 | |||||||||
| Women | Nowak et al. 1988 [ | US | 50 | 561 | 42 (22–66) | <0.01 | 94 | 0 | 42 (22–66) | ||
| Neiman et al. 1989 [ | US | 27 | |||||||||
| Peters and Goetzsche 1997 [ | South African | 83 | |||||||||
| Sekulic et al. 2008 [ | Serbian | 24 | |||||||||
| Knez and Peake 2010 [ | Mixed | 69 | |||||||||
| Karimian et al. 2011 [ | Iranian | 11 | |||||||||
| Dolan et al. 2011 [ | US | 53 | |||||||||
| MVM | Elite | Men | Houston 1980 [ | Canadian | 50 | 218 | 56 (50–63) | 0.91 | 0 | 0 | 56 (50–63) |
| Rosen et al. 1999 [ | Norwegian | 57 | |||||||||
| Ziegler et al. 2003 [ | US | 61 | |||||||||
| Kim et al. 2011 [ | Korean | 56 | |||||||||
| Women | Houston 1980 [ | Canadian | 42 | 192 | 58 (31–81) | <0.01 | 90 | 0 | 58 (31–81) | ||
| Rosen et al. 1999 [ | Norwegian | 26 | |||||||||
| Ziegler et al. 2003 [ | US | 83 | |||||||||
| Kim et al. 2011 [ | Korean | 72 | |||||||||
| Non elite | Men | Sandoval et al. 1989 [ | US | 20 | 1397 | 33 (26–41) | <0.01 | 87 | 0 | 33 (26–41) | |
| Nieman et al. 1989 [ | US | 22 | |||||||||
| Worme et al. 1990 [ | US | 30 | |||||||||
| Krumbach et al. 1999 [ | US | 41 | |||||||||
| Froiland et al. 2004 [ | US | 22 | |||||||||
| Kristiansen et al. 2005 [ | Canadian | 52 | |||||||||
| Kim et al. 2011 [ | Korean | 30 | |||||||||
| Dolan et al. 2011 [ | US | 40 | |||||||||
| Women | Sandoval et al. 1989 [ | US | 50 | 735 | 39 (30–49) | <0.01 | 83 | 2 | 34 (24–44) | ||
| Nieman et al. 1989 [ | US | 20 | |||||||||
| Worme et al. 1990 [ | US | 57 | |||||||||
| Krumbach et al. 1999 [ | US | 43 | |||||||||
| Froiland et al. 2004 [ | US | 26 | |||||||||
| Kristiansen et al. 2005 [ | Canadian | 63 | |||||||||
| Kim et al. 2011 [ | Korean | 30 | |||||||||
| Dolan et al. 2011 [ | US | 39 | |||||||||
| Vitamin C | Elite | Men | Houston 1980 [ | Canadian | 38 | 44 | 36 (26–48) | 0.94 | 0 | a | a |
| Rosen et al. 1999 [ | Norwegian | 37 | |||||||||
| Women | Houston 1980 [ | Canadian | 25 | 43 | 30 (23–40) | 0.67 | 0 | a | a | ||
| Rosen et al. 1999 [ | Norwegian | 31 | |||||||||
| Non elite | Men | Neiman et al. 1989 [ | US | 14 | 1015 | 17 (14–20) | 0.22 | 32 | 0 | 17 (14–20) | |
| Krumbach et al. 1999 [ | US | 20 | |||||||||
| Froiland et al. 2004 [ | US | 18 | |||||||||
| Kim et al. 2011 [ | Korean | 15 | |||||||||
| Women | Neiman et al. 1989 [ | US | 7 | 425 | 17 (12–25) | 0.03 | 67 | 1 | 20 (13–29) | ||
| Krumbach et al. 1999 [ | US | 24 | |||||||||
| Froiland et al. 2004 [ | US | 14 | |||||||||
| Kim et al. 2011 [ | Korean | 21 | |||||||||
CI confidence interval, DS dietary supplement, MVM multivitamin/multimineral, SPE summary prevalence estimate, S95 % CI summary 95 % CI
aNot calculated with fewer than four studies
Prevalence of dietary supplement use in combined athletic groups
| Dietary supplement | Sex | Studies ( | SPE [% (S95 % CI)] | Homogeneity of SPE | Trim and fill evaluation | ||
|---|---|---|---|---|---|---|---|
|
|
| Imputed studies ( | Adjusted SPE [% (S95 % CI)] | ||||
| Any DS | M and F | 61 | 60 (55–64) | <0.01 | 97 | 4 | 58 (54–63) |
| M | 34 | 62 (56–69) | <0.01 | 95 | 2 | 60 (54–67) | |
| F | 31 | 58 (50–65) | <0.01 | 92 | 2 | 57 (49–64) | |
| Any vitamin/mineral | M and F | 22 | 50 (43–57) | <0.01 | 91 | 1 | 49(42–57) |
| M | 9 | 50 (41–60) | <0.01 | 85 | 2 | 47 (37–57) | |
| F | 14 | 52 (43–62) | <0.01 | 82 | 1 | 49 (40–59) | |
| MVM | M and F | 44 | 34 (30–40) | <0.01 | 96 | 2 | 33 (28–38) |
| M | 21 | 37 (31–44) | <0.01 | 90 | 2 | 36 (19–32) | |
| F | 25 | 36 (29–44) | <0.01 | 88 | 2 | 35 (26–44) | |
| Vitamin A | M and F | 10 | 6 (4–7) | <0.01 | 91 | 1 | 6 (4–10) |
| M | 6 | 4 (2–8) | <0.01 | 88 | 1 | 5 (2–9) | |
| F | 5 | 3 (1–10) | <0.01 | 86 | 2 | 5 (2–13) | |
| Vitamin B or B complex | M and F | 24 | 17 (12–23) | <0.01 | 96 | 0 | 17 (12–23) |
| M | 12 | 18 (11–28) | <0.01 | 95 | 0 | 18 (11–28) | |
| F | 10 | 15 (9–23) | <0.01 | 85 | 1 | 17 (11–26) | |
| Vitamin C | M and F | 34 | 32 (26–39) | <0.01 | 96 | 1 | 33 (27–39) |
| M | 18 | 34 (25–44) | <0.01 | 97 | 0 | 34 (25–44) | |
| F | 20 | 31 (25–38) | <0.01 | 84 | 8 | 41 (35–49) | |
| Vitamin D | M and F | 10 | 7 (3–15) | <0.01 | 96 | 0 | 7 (3–15) |
| M | 5 | 10 (3–32) | <0.01 | 94 | 0 | 10 (3–32) | |
| F | 3 | 7 (2–28) | <0.01 | 86 | a | a | |
| Vitamin E | M and F | 24 | 13 (10–18) | <0.01 | 94 | 3 | 16 (12–21) |
| M | 10 | 14 (8–23) | <0.01 | 92 | 1 | 16 (10–25) | |
| F | 7 | 8 (4–15) | <0.01 | 79 | 1 | 9 (5–17) | |
| Iron | M and F | 30 | 17 (12–23) | <0.01 | 95 | 0 | 17 (12–23) |
| M | 10 | 11 (5–24) | <0.01 | 96 | 0 | 11 (5–24) | |
| F | 18 | 23 (15–34) | <0.01 | 94 | 0 | 23 (15–34) | |
| Calcium | M and F | 25 | 12 (8–18) | <0.01 | 94 | 5 | 15 (11–22) |
| M | 7 | 20 (7–47) | <0.01 | 97 | 0 | 20 (7–47) | |
| F | 14 | 17 (11–25) | <0.01 | 90 | 3 | 21 (14–30) | |
| Zinc | M and F | 10 | 7 (5–10) | <0.01 | 80 | 0 | 7 (5–10) |
| M | 5 | 7 (4–12) | 0.01 | 68 | 0 | 7 (4–12) | |
| F | 5 | 5 (2–13) | <0.01 | 81 | 2 | 8 (3–17) | |
| Protein | M and F | 33 | 27 (20–35) | <0.01 | 98 | 0 | 27 (20–35) |
| M | 20 | 36 (25–49) | <0.01 | 78 | 1 | 37 (25–50) | |
| F | 15 | 12 (7–22) | <0.01 | 95 | 0 | 12 (7–22) | |
| Amino acid | M and F | 24 | 15 (12–20) | <0.01 | 97 | 0 | 15 (12–20) |
| M | 15 | 15 (9–23) | <0.01 | 96 | 0 | 15 (9–23) | |
| F | 10 | 10 (3–23) | <0.01 | 96 | 0 | 10 (3–23) | |
| Creatine | M and F | 24 | 14 (10–20) | <0.01 | 97 | 0 | 14 (10–20) |
| M | 18 | 17 (11–26) | <0.01 | 97 | 3 | 20 (13–30) | |
| F | 14 | 3 (1–4) | <0.01 | 53 | 5 | 3 (2–6) | |
|
| M and F | 7 | 12 (4–29) | <0.01 | 97 | 0 | 12 (4–29) |
| M | 3 | 11 (3–40) | <0.01 | 87 | a | a | |
| F | 4 | 13 (2–60) | <0.01 | 96 | 0 | 13 (2–60) | |
| Ginseng | M and F | 9 | 8 (5–14) | <0.01 | 96 | 1 | 9 (5–15) |
| M | 5 | 10 (6–17) | <0.01 | 89 | 0 | 10 (6–17) | |
| F | 5 | 8 (3–20) | <0.01 | 94 | 0 | 8 (3–20) | |
| Sport drink | M and F | 17 | 28 (18–24) | <0.01 | 98 | 0 | 28 (18–24) |
| M | 10 | 44 (24–66) | <0.01 | 96 | 0 | 44 (24–66) | |
| F | 8 | 35 (22–51) | <0.01 | 89 | 0 | 35 (22–51) | |
| Sport bar | M and F | 9 | 34 (22–47) | <0.01 | 95 | 0 | 34 (22–47) |
| M | 7 | 28 (14–56) | <0.01 | 96 | 0 | 28 (14–28) | |
| F | 3 | 32 (12–62) | <0.01 | 96 | 0 | 32 (12–62) | |
| Ω-3-fatty acid supplement | M and F | 6 | 14 (8–24) | <0.01 | 94 | 1 | 18 (10–28) |
| M | 4 | 21 (12–31) | <0.01 | 91 | 1 | 25 (15–39) | |
| F | 3 | 20 (12–32) | <0.01 | 79 | a | a | |
| Energy drinkb | M and F | 3 | 34 (26–43) | <0.01 | 71 | a | a |
| Caffeine | M and F | 4 | 29 (16–46) | <0.01 | 94 | 1 | 24 (2–41) |
| M | 2 | 20 (16–26) | 0.73 | 0 | a | a | |
| F | 2 | 21 (16–24) | 0.14 | 54 | a | a | |
DS dietary supplement, F females, M males, MVM multivitamin/multimineral, SPE summary prevalence estimate, S95 % CI summary 95 % confidence interval
aNot calculated with fewer than four studies
bNo study reported men and women separately
Summary data on dietary supplement use in US national surveys
| Survey | Study | Survey year(s) |
| Reporting timeframe | Prevalence (%) | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Any VM | MVM | Vitamin C | ||||||||
| M | W | M | W | M | W | |||||
| National Health Interview Survey (NHIS) | Subar and Block 1990 [ | 1987 | 9160 M, 12,920 F | Daily use | 19 | 27 | 15 | 20 | 7 | 8 |
| Slesinski et al. 1995 [ | 1992 | 5120 M, 6885 F | Daily use | 20 | 27 | 17 | 22 | 7 | 8 | |
| Millens et al. 2004 [ | 2000 | 34,085 M and F | Daily use | 29 | 39 | 24 | 33 | 10 | 12 | |
| National Health and Nutrition Survey (NHANES) | Koplan et al. 1986 [ | 1976–1980 | 5915 M, 6588 F | Use ≥1 time/wk | 30 | 40 | ND | ND | ND | ND |
| Balluz et al. 2000 [ | 1988–1994 | 33,905 M and F | Use in last month | 35 | 44 | ND | ND | ND | ND | |
| Radimer et al. 2004 [ | 1999–2000 | 2260 M, 2602 F | Use in last month | 46 | 57 | 32 | 38 | 12 | 13 | |
| Kennedy et al. 2013 [ | 2007–2008 | 3364 M and F | Use in last month | 42 | 54 | ND | ND | ND | ND | |
VM vitamin and/or mineral, MVM multivitamin/multimineral, M males, F females, ND no data, wk week
| When dietary supplement use was compiled by sport, elite versus non-elite athletic status, and supplement type there was high variability in use prevalence among studies. |
| Elite athletes appeared to use dietary supplements much more than their non-elite counterparts. |
| For most dietary supplements, use prevalence appeared similar for men and women. Exceptions were that a larger proportion of women used iron and a larger proportion of men used vitamin E, protein, and creatine. |